Streetbeat News

Products Services

BLTE

Belite Bio has presented the final data from a 24-month, Phase 2 study of Tinlarebant in childhood-onset Stargardt disease at the American Association of Ophthalmology Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:05 pm

ATNM

Actinium Pharmaceuticals has presented data at the Society of Immunotherapy of Cancer Annual Meeting for Actimab-A, a targeted radiotherapeutic comprised of the CD33 targeting antibody Lintuzumab and the Actinium-225 alpha-particle emitting payload.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:01 pm

ACN

CRM

Accenture and Salesforce have partnered to help life sciences companies differentiate themselves using data and AI. The partnership aims to improve patient experiences and outcomes by leveraging Salesforce's Health Cloud and Accenture's Intient platform.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:00 pm

BKYI

BIO-key has been awarded an $800K follow-on order for biometric user authentication from a government defense ministry. This is expected to boost the company's revenues and strengthen its position in the biometric security market.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:00 pm

AAPL

WLDS

Wearable Devices has announced a new technology feature for its Mudra Band, which will allow users to control Apple TV devices using touchless hand movements.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:55 pm

NSSC

NAPCO Security Technologies expects radio sales to continue to be a key contributor to its hardware sales as FY24 progresses. The company has reported an improved gross margin for hardware sales of 28% and expects this to improve further. The net income margin and Adjusted EBITDA margin are 25% and 31% respectively. The company will continue its dividend program, paying a dividend of $0.08 per share on December 22, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:55 pm

IFRX

InflaRx has announced that the first patient has been dosed in its Phase 3 study investigating the efficacy and safety of Vilobelimab in Pyoderma Gangrenosum. This marks a significant milestone in the development of the drug.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:36 pm

ABOS

HALO

Acumen Pharmaceuticals, Inc. and Halozyme have entered a global collaboration and license agreement to develop a subcutaneous formulation of ACU193 with ENHANZE technology.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:31 pm

BMWYY

TSLA

BMW (OTC:BMWYY) has claimed that its latest battery designs surpass those of Tesla Inc. (NASDAQ:TSLA). BMW's forthcoming cylindrical battery cell samples are projected to deliver 20% more energy and up to a 30% increase in range, slash costs by 50%, and reduce production-related carbon emissions by 60%. Despite Tesla surpassing BMW as the top luxury car in the U.S. for 2022, BMW’s latest battery technology and production plans demonstrate the company’s commitment to close the gap with Tesla and strengthen its position in the EV market.

Portfolio Pulse from Benzinga Neuro

November 06, 2023 | 12:26 pm

MSFT

OpenAI, backed by Microsoft Corp. (NASDAQ:MSFT), is reportedly developing a feature that allows users to create and share their own GPT models. The feature, known as 'Magic Maker', is expected to be powered by GPT-4 Magic Create, enabling users to design a unique GPT that meets their specific needs. Users can save their customized GPTs for individual use or distribute them to others via a link. This development could potentially create an ecosystem of GPT developers and consumers.

Portfolio Pulse from Rounak Jain

November 06, 2023 | 12:23 pm